BioSyngen is a flagship biopharmaceutical enterprise linked to the Singapore Agency for Science, Technology, and Research (A*STAR). BioSyngen is dedicated toward developing a conduit between Singapore and China, so as to establish platforms for technology transfer and pathways for product development. At the same time, our company also focuses on Tumor Immunotherapy and Drug Develop using the three pronged approach of Cell Engineering, Immune Engineering and Genetic Engineering. BioSyngen has access to a decorated team of international scientific advisers and corroborators. This includes 2011 Nobel Laureate Professor Jules Alphonse Hoffman, Research Director CNRS Emeritus at CNRS Professor Jean-Paul Thiery, and Fellow of the Royal Society Professor Sir David Lane. BioSyngen, founded in 2016, has since transformed into a holding company in early 2019. We aim to complete our Series A funding to booster sole-propriety/avant-garde tumour immune therapy, and products such as cell therapy, tumour genetics and in-vitro protein detection, for clinical trials in countries including Singapore, Australia and China. BioSyngen aims to attain Unicorn status and IPO listing by 2021.
BioSyngen is a flagship biopharmaceutical enterprise linked to the Singapore Agency for Science, Technology, and Research (A*STAR). BioSyngen is dedicated toward developing a conduit between Singapore and China, so as to establish platforms for technology transfer and pathways for product development. At the same time, our company also focuses on Tumor Immunotherapy and Drug Develop using the three pronged approach of Cell Engineering, Immune Engineering and Genetic Engineering. BioSyngen has access to a decorated team of international scientific advisers and corroborators. This includes 2011 Nobel Laureate Professor Jules Alphonse Hoffman, Research Director CNRS Emeritus at CNRS Professor Jean-Paul Thiery, and Fellow of the Royal Society Professor Sir David Lane. BioSyngen, founded in 2016, has since transformed into a holding company in early 2019. We aim to complete our Series A funding to booster sole-propriety/avant-garde tumour immune therapy, and products such as cell therapy, tumour genetics and in-vitro protein detection, for clinical trials in countries including Singapore, Australia and China. BioSyngen aims to attain Unicorn status and IPO listing by 2021.
BioSyngen is a flagship biopharmaceutical enterprise linked to the Singapore Agency for Science, Technology, and Research (A*STAR). BioSyngen is dedicated toward developing a conduit between Singapore and China, so as to establish platforms for technology transfer and pathways for product development. At the same time, our company also focuses on Tumor Immunotherapy and Drug Develop using the three pronged approach of Cell Engineering, Immune Engineering and Genetic Engineering. BioSyngen has access to a decorated team of international scientific advisers and corroborators. This includes 2011 Nobel Laureate Professor Jules Alphonse Hoffman, Research Director CNRS Emeritus at CNRS Professor Jean-Paul Thiery, and Fellow of the Royal Society Professor Sir David Lane. BioSyngen, founded in 2016, has since transformed into a holding company in early 2019. We aim to complete our Series A funding to booster sole-propriety/avant-garde tumour immune therapy, and products such as cell therapy, tumour genetics and in-vitro protein detection, for clinical trials in countries including Singapore, Australia and China. BioSyngen aims to attain Unicorn status and IPO listing by 2021.